30,333 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Purchased by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans bought a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 30,333 shares of the company’s stock, valued at approximately $679,000.

Other large investors also recently modified their holdings of the company. Blue Trust Inc. grew its stake in shares of Intellia Therapeutics by 1,664.3% in the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock worth $33,000 after purchasing an additional 1,398 shares during the last quarter. First Horizon Advisors Inc. grew its stake in shares of Intellia Therapeutics by 22.1% in the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after purchasing an additional 472 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Intellia Therapeutics by 1,322.0% in the second quarter. GAMMA Investing LLC now owns 2,645 shares of the company’s stock worth $59,000 after purchasing an additional 2,459 shares during the last quarter. EntryPoint Capital LLC grew its stake in shares of Intellia Therapeutics by 61.1% in the first quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock worth $113,000 after purchasing an additional 1,563 shares during the last quarter. Finally, AdvisorNet Financial Inc boosted its position in Intellia Therapeutics by 63.5% during the 2nd quarter. AdvisorNet Financial Inc now owns 5,100 shares of the company’s stock valued at $114,000 after acquiring an additional 1,980 shares in the last quarter. 88.77% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 3.00% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of NTLA stock opened at $17.84 on Tuesday. The company has a market capitalization of $1.72 billion, a P/E ratio of -3.33 and a beta of 1.76. The company’s 50-day simple moving average is $21.82 and its two-hundred day simple moving average is $23.41. Intellia Therapeutics, Inc. has a one year low of $17.43 and a one year high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The firm had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $19.68 million. The business’s quarterly revenue was down 48.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.40) EPS. On average, research analysts expect that Intellia Therapeutics, Inc. will post -5.22 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on NTLA shares. StockNews.com raised Intellia Therapeutics to a “sell” rating in a research report on Thursday, June 27th. JPMorgan Chase & Co. cut their price objective on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 24th. Stifel Nicolaus cut their price objective on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday, September 11th. Finally, Truist Financial reaffirmed a “buy” rating and set a $120.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $61.77.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.